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Abstract 
Objective: The purpose of this study was to investigate the correlation between 
the Controlling Nutritional Status (CONUT) score and survival of patients with 
localized urothelial carcinoma of the upper urinary tract (UTUC) treated with 
radical nephroureterectomy (RNU). 
Methods and Materials: We retrospectively enrolled 107 patients. CONUT score 
was calculated based on the serum albumin concentration, lymphocyte count, 
and total cholesterol concentration. Patients were classified into two groups 
based on CONUT score. Relapse-free survival (RFS), cancer-specific survival 
(CSS), and overall survival (OS) after RNU were compared between the two 
groups, and predictors of survival were analyzed using Cox proportional hazards 
regression models. 
Results: For CONUT score, the area under the curve was 0.588, and the optimal 
cutoff value was 3. Twenty-four patients (22.4%) had high CONUT scores. The 
patients with high CONUT scores had significantly shorter 5-year RFS, CSS, and 
OS than did those with low CONUT scores (RFS: 50.1% vs. 66.0%, CSS: 28.1% 
vs. 71.7%, OS: 26.4% vs. 66.8%, all p < 0.05). Results of the multivariable 
analysis, after adjustment for factors such as pT stage, pN stage, tumor grade, 
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presence of lymphovascular invasion, and C-reactive protein level, revealed that 
CONUT score was an independent predictor of CSS (hazard ratio [HR], 5.44; p 
= 0.0016) and OS (HR, 2.90; p = 0.0214), and showed marginal significance for 
predicting RFS (HR, 2.26; p = 0.0581).  
Conclusions: Preoperative CONUT score helps predict survival in patients with 
localized UTUC treated with RNU.  
 
Highlights  
 The CONUT score’s prediction of patient survival after RNU is unknown. 
 The CONUT score was associated with RFS, CSS, and OS after RNU for 
localized UTUC. 
 The CONUT score helps predict RFS, CSS, and OS after RNU for localized 
UTUC. 
 The score’s impact remains after adjusting for tumor-specific factors and CRP. 
 There was a close relationship between sarcopenia and CONUT score. 
 
Keywords: Biomarker; inflammation; nutrition; urothelial carcinoma; 
nephroureterectomy; survival  
5 
 
1. Introduction  
 It is well recognized that the development of cancer has a genetic basis, 
however, there is increasing evidence that host inflammatory responses also play 
an important role in cancer’s development and progression [1-3]. The hyper-
catabolic state and inflammatory response that are caused by malignancy also 
exacerbates malnutrition [1]. In this context, a prognostic biomarker representing 
nutritional condition is identified as an independent predictor of survival in patients 
with cancer. Recently, the Controlling Nutritional Status (CONUT) score, which is 
an index calculated from the serum albumin concentration, total peripheral 
lymphocyte count, and total cholesterol concentration, has received focus as a 
predictive biomarker of survival in patients with several cancers [4-6]. For 
example, in a cohort of 204 patients with stage II/ III colorectal cancer undergoing 
curative surgery, Iseki et al. reported that the 5-year cancer-specific survival 
(CSS) rate was significantly higher in the low CONUT group than in the high 
CONUT group (92.7% vs. 81.0%), and multivariate analyses showed that high 
CONUT scores independently predicted low CSS rates [4].   
We previously reported that sarcopenia, which was an indicator of cancer 
cachexia, was significantly associated with prognosis in patients with localized 
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urothelial carcinoma of the upper urinary tract (UTUC) after radical 
nephroureterectomy (RNU) [7] . This finding suggested a relationship between 
malnutrition and poor prognosis in patients with UTUC after RNU, as a sarcopenic 
status indicates patient frailty and malnutrition caused by systematic inflammation. 
Thus, we investigated whether the CONUT score, which was developed to 
evaluate immune-nutritional status, could predict survival in patients with 
localized UTUC after RNU.  
 
2. Material and methods  
2.1. Study design  
The Internal Ethics Review Board of Tokyo Women’s Medical University 
approved this retrospective single-center study (ID 4204), which was performed 
in accordance with the principles outlined in the Declaration of Helsinki.  
In our department, 200 patients overall underwent RNU for localized UTUC (i.e., 
cTanyN0M0) between October 2003 and March 2014. Among these patients, 42 
patients who had prior UC (bladder: 36 patients, UTUC: 6 patients), 7 who 
received neoadjuvant chemotherapy, 10 who received hemodialysis therapy, and 
34 who did not have available clinical data were excluded. The remaining 107 
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patients were evaluated in this study (Figure 1).  
 Clinical and laboratory data were extracted from an electronic database and the 
patient medical record. Our diagnostic strategy is largely based on a consensus 
guideline [8]; all patients undergo urinary cytology examination, computed 
tomography and/or magnetic resonance imaging (if possible, enhanced) of the 
chest, abdomen, and pelvis, and cystoscopy to rule out concomitant bladder 
tumors. Retrograde ureteropyelography, ureteroscopy or biopsy is performed 
only when tumor location is not clarified or the possibility of benign lesions cannot 
be excluded. Staging of the tumor was performed based on the Union for 
International Cancer Control TNM classification [9]. The preoperative stage was 
diagnosed based on computed tomography findings of the chest, abdomen, and 
pelvis. Surgery was performed based on the procedure for the management of 
urothelial tumors of the renal pelvis and ureter, as described in Campbell’s 
Urology [10]. Open standard nephroureterectomy and retroperitoneoscopic 
surgery were performed in conjunction with open distal ureter and bladder cuff 
removal at our institution. All tumors were confirmed to be urothelial carcinoma 
using histology. After RNU, patients were evaluated for recurrence by computed 
tomography every 6 months and for intravesical recurrence with cystoscopy and 
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urine cytology every 3 months for the first 2 years. Subsequently, follow-up 
examinations were performed every 6-12 months. 
  
2.2. Endpoint  
Relapse-free survival (RFS), CSS and overall survival (OS) after RNU were set 
as endpoints in this study. RFS was defined as the time from RNU to the first local 
recurrence, metastasis, or any-cause death. CSS and OS were defined as the 
time from RNU to cancer-related or any-cause death, respectively.  
 
2.3. Defining of CONUT score  
 In all patients, blood samples were obtained within 2 months before RNU. The 
CONUT score was calculated from the serum albumin concentration, total 
peripheral lymphocyte count, and total cholesterol concentration, as shown in 
Table 1. These three parameters were evaluated from the same blood sample.  
The efficacy of using the CONUT score was analyzed using the receiver 
operating characteristic (ROC) curve and the area under curve (AUC). The cutoff 
value for the CONUT score was defined using the maximum Youden index [11].  
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2.4 Protocol for regional lymphadenectomy  
We simultaneously performed regional lymphadenectomy (LND) with RNU for 
patients with localized UTUC, expect for patients with severe comorbidities or at 
an advanced age, as described previously [12, 13]. The right renal hilar, 
paracaval, retrocaval, and interaortocaval nodes were dissected for right pelvic 
and right upper and middle ureteral tumors. The left renal hilar and para-aortic 
nodes were dissected for left renal pelvic and left upper and middle ureteral 
tumors. The lower boundary of the template was defined as the level of the 
inferior mesenteric artery for pelvic tumors, and as the aortic bifurcation for upper 
and middle ureteral tumors. The ipsilateral common iliac, external iliac, obturator, 
internal iliac and presacral nodes were included for lower ureteral tumors. All 
LNDs were performed as an open procedure, and the lymph node specimens 
were sampled en bloc with the surrounding adipose tissue. 
 
2.5 Adjuvant chemotherapy 
Adjuvant chemotherapy was considered for nodal involvement and/or disease 
infiltrating surrounding adipose tissue, with considering of the patients’ 
comorbidities, performance status, and willingness to receive therapy. The 
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chemotherapy regimen was 1-3 cycles of methotrexate, vinblastine, doxorubicin, 
and cisplatin or 1-3 cycles of gemcitabine and cisplatin. 
 
2.6 Definition of sarcopenia 
Sarcopenia has been defined in detail previously [7, 14]. Briefly, preoperative 
computed tomography was used to calculate skeletal muscle index, which 
indicates whole-body muscle mass. Sarcopenia was defined using sex-specific 
consensus definitions, based on the patient’s skeletal muscle and body mass 
indexes. 
 
2.7 Statistical analysis 
 Data for the two groups were compared using the χ2 test or Mann-Whitney U 
test, as appropriate. RFS, CSS, and OS curves were estimated using the Kaplan-
Meier method and compared using the log-rank test. We performed multivariable 
analyses for RFS, CSS, and OS to assess associations between 
clinicopathological parameters, including CONUT score and outcomes, using 
Cox proportional hazards regression models. Risk was expressed as hazard 
ratios (HRs) and 95% confidence intervals (CIs). All analyses were performed 
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using JMP software (ver. 11; SAS Institute Inc., Cary, NC, USA), and differences 
were considered statistically significant at a p-value of < 0.05. 
 
3. Results 
3.1 ROC curve analysis and cutoff value for CONUT score  
The ROC analysis for the CONUT score showed that the AUC predicting RFS 
was 0.588 (Figure 2). According to the maximum Youden index value, the cutoff 
for CONUT score was set at 3; therefore, 24 patients with a CONUT score ≥ 3 
were classified into the high CONUT score group, whereas the remaining 83 
patients (i.e., those with CONUT scores < 3) were classified into the low CONUT 
score group. 
 
3.2 CONUT score components 
 Table 2 shows the individual CONUT score components for the high and low 
CONUT score groups. As expected, patients in high CONUT group had higher 
scores for the 3 components than those in the low CONUT group.  
 
3.3 Patients’ backgrounds 
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 Table 3 shows the patients’ backgrounds. High CONUT score was significantly 
associated with high serum CRP level (p = 0.0041) and sarcopenia (p = 0.0213), 
whereas there were no significant differences in other clinicopathological 
parameters between the high and low CONUT score groups, including age, sex, 
initial symptoms, tumor site, surgical approach, pT stage, pN stage, tumor grade, 
presence of lymphovasular invasion (LVI), or the presence of adjuvant 
chemotherapy (all p > 0.05). Adjuvant chemotherapy was administered in 5 and 
3 patients with ≥T3 stage and with both ≥T3 and ≥N1 stage, respectively. LND 
was performed and ≥N1 stage was observed significantly more often in patients 
receiving than in those not receiving adjuvant chemotherapy (LND: 100% vs. 
47.5%, p = 0.0042; ≥N1 stage: 37.5% vs. 6.06%, p = 0.0021). During follow-up, 
34 patients experienced cancer recurrence, and 25 and 32 patients died from 
cancer and any cause, respectively. These rates were non-significantly higher in 
patients with high CONUT scores (RFS: 41.7% vs. 28.9%; CSS: 37.5% vs. 
19.3%; OS; 41.7% vs. 26.5%, all p > 0.05). Finally, follow-up duration was 
significantly shorter in the high CONUT score group than in the low CONUT score 
group (p = 0.0045), perhaps due to their shorter CSS/OS. 
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3.4 Survival according to CONUT score 
 In the 34 patients (31.8%) with cancer relapse, contralateral recurrence and 
local recurrence or lymph node/distance metastasis were observed in 4 (37.4%) 
and 30 (28.0%) patients, respectively. Chemotherapy, radiation, and 
metastatectomy were performed in 19, 6, and 2 patients, respectively, whereas 
best supportive care for reduced performance status was performed in 12 
patients. There were no significant differences between high and low CONUT 
groups in the rates of patients undergoing each treatment (chemotherapy: 7 
[70.0%] vs. 12 [50.0%], p = 0.285; radiation: 4 [16.7%] vs. 2 [20.0%], p = 0.816; 
metastatectomy: 1 [10.0%] vs. 1 [4.17%], p = 0.510; best supportive care: 3 
[30.0%] vs. 9 [37.5%], p = 0.677). Figure 3 shows that patients with high CONUT 
score had significantly shorter RFS, CSS, and OS after RNU than patients with 
low CONUT score did (5-year RFS: 50.1% vs. 66.0%, p = 0.0395; CSS: 28.1% 
vs. 71.7%, p = 0.0041; OS: 26.4% vs. 66.8%, p = 0.0140).  
 
3.5 Predictors for survival  
Univariable analyses for RFS, CSS, and OS showed that pT stage, pN stage, 
tumor grade, presence of LVI, serum CRP level, and CONUT score were 
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significantly associated with survival (all p < 0.05), whereas other parameters, 
including age, sex, tumor site, surgical approach, or presence of adjuvant 
chemotherapy were not significantly associated with survival. Multivariable 
analyses showed that CONUT score was an independent predictor for CSS and 
OS (CSS: HR 5.44; p = 0.0016; OS: HR 2.90; p = 0.0214), whereas CONUT 
score marginally significantly predicted RFS (HR 2.26; p = 0.0581). With respect 
to other parameters, pT stage was significantly associated with CSS and OS 
(CSS: HR 12.9; p = 0.0002; OS: HR 3.29; p = 0.0167), and pN stage was 
significantly associated with RFS (HR 3.59; p = 0.0080) (Table 4). 
 
4. Discussion  
 We found that the preoperative CONUT score helped predict RFS, CSS, and 
OS after RNU for UTUC. Importantly, we found that the CONUT score remained 
a significantly predictive biomarker after adjusting for tumor-specific factors (i.e., 
pT stage, pN stage, tumor grade, and presence of LVI), which are well-known risk 
factors [15, 16]. Moreover, its influence remained after adjustment for pre-
treatment CRP level, which is a typical inflammatory-based biomarker that has 
been identified as being associated with prognosis in patients with UTUC [17, 18].  
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The predictive impact of CONUT score for prognosis has been previously 
demonstrated in colorectal cancer [4] and thoracic esophageal squamous cell 
carcinoma [5, 6]. After Iseki and colleagues reported the CONUT score’s 
predictive role in patients with localized colorectal cancer [4], Toyokawa and 
Hirahara et al. suggested that it independently predicted RFS and OS, and was 
superior to other inflammation-based markers, such as the platelet/lymphocyte 
ratio, neutrophil/lymphocyte ratio, and modified Glasgow prognostic score, in 
patients with resectable thoracic esophageal squamous cell carcinoma [5, 6]. 
However, the predictive influence of the CONUT score on prognosis in patients 
with genitourinary cancers, such as UTUC, has remained controversial. Thus, to 
the best of our knowledge, this is the first study showing that the preoperative 
CONUT score was significantly associated with patient survival after RNU for 
localized UTUC.  
 The CONUT score is determined based on the serum albumin concentration, 
total lymphocyte count, and total cholesterol concentration. Low albuminemia 
was previously reported to be associated with poor prognosis in patients with 
cancer. Albumin concentration represents not only nutritional status but also other 
factors, including inflammation, caused by cancer cells [19, 20]. Numerous 
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studies of various cancers have investigated the predictive role of inflammation-
based markers that incorporate albumin (e.g., the modified Glasgow prognostic 
score or CRP/albumin ratio) [14, 21, 22]. Moreover, lymphocytes play a role in 
the host’s immunity against cancers and are thought to possess an antitumor 
effect by inducing cell apoptosis, suppressing tumor growth and migration, and 
mediating cytotoxicity [3]. T-lymphocytes play an important role in the immune 
response to cancer. Previous studies have indicated that high intratumoral CD8+ 
T-cell density was associated with better prognosis in invasive urothelial 
carcinoma of the bladder [23]. Moreover, patients with invasive bladder cancer 
had lower tumor infiltration of CD4+ and CD8+ T-cells [24], and in patients who 
responded to chemotherapy for bladder urothelial carcinoma, the CD4+/CD8+ 
ratio was significantly higher than that in those who did not respond [25]. A recent 
study indicated that a lower pre-treatment neutrophil/lymphocyte ratio might 
indicate good outcomes after neoadjuvant chemotherapy in muscle-invasive 
bladder cancer [26]. Finally, low serum cholesterol levels have been reported to 
be associated with a poor prognosis in patients with cancers [27-29]. Although it 
remains unclear why hypocholesterolemia is associated with a poor prognosis, 
there are several speculations based on previous experimental studies; 
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cholesterol is a crucial membrane component, and it affects membrane structure 
and function, including membrane fluidity and membrane protein activity [30-32]. 
Cholesterol metabolism is strictly regulated to maintain an appropriate cholesterol 
content in healthy cells. Perturbations in cholesterol metabolism can play 
important roles in oncogenesis and tumor development [33, 34]. Indeed, a 
previous experimental study suggested that membrane lipid composition plays 
an important role in urothelial carcinoma progression [35]. One of the sources of 
cholesterol is its acquisition from circulating blood via low-density lipoprotein 
(LDL) receptor-mediated endocytosis [36]. LDL receptor activity is reported to be 
elevated in patients with cancer, indicating that tumor-associated 
hypocholesteremia might result from increased cholesterol uptake by the 
neoplastic cells of neoplasms [37, 38]. Additionally, an elevated serum 
interleukin-6 level, which is induced by cancer cells [39], is reported to be 
associated with a decreased serum cholesterol level [40].  
 Finally, a unique aspect of this study was its demonstration of the relationship 
between sarcopenia and CONUT score (Table 3). Sarcopenia involves 
degenerative skeletal muscle wasting, and has recently been recognized as an 
important physiological change occurring during cancer cachexia development 
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[41]. Although sarcopenia occurs during normal aging, it can be exacerbated by 
hypercatabolic states and inflammatory responses caused by malignancy [1]. 
Thus, as expected, we observed a close relationship between sarcopenic status 
and high CONUT score, because these two markers similarly represented high 
inflammatory or malnutrition.     
This study has several limitations. First, it was performed in a small cohort using 
a retrospective, single-center design. Second, because of its retrospective nature, 
potential factors that could possibly affect inflammation-based markers, such as 
comorbidities or medications, could not be completely excluded. Therefore, large-
scale prospective validation studies are needed to confirm our findings. Third, a 
study recently reported the effect of CONUT score on cardiovascular morbidity 
[42], which could represent a competing risk in our analyses. Indeed, 7 patients 
died from non-cancer-related causes; 6 with low CONUT scores (subarachnoid 
hemorrhage, renal failure, colon cancer, pneumonia, abdominal aneurysm, and 
unknown) and 1 with a high CONUT score (heart failure). Because only 1 patient 
in each group died from cardiovascular disease, a competing risk of CONUT 
score on cardiovascular morbidity did not appear strong. Nonetheless, this 
possible influence should be considered. Fourth, only severe lymphocytopenia 
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(e.g., <800/mm3; score 3) could result in a high CONUT score due to this marker’s 
nature. Indeed, as shown in Table 2, only 7 (29.2%) patients had it, however, 3 
had other components (i.e., low albumin and/or cholesterol); therefore, CONUT 
score can comprehensively represent nutritional status, although a strong 
influence of lymphocytopenia on high CONUT score may exist. Fifth, we found a 
higher rate of LVI (54 patients [50.5%]); this percentage was higher than those 
reported previously. Although we do not have an adequate explanation, we 
believe that this may have affected the analyses. Sixth, our analyses showed that 
30 patients (28.0%) underwent RNU despite the presence of low-grade cancer; 
this may also have affected the analyses because of possible overtreatment. 
However, this can be partly attributed to the retrospective nature of our study. We 
could not diagnose low-grade cancer until RNU was performed because we do 
not routinely perform ureteroscopy or retrograde ureteropyelography. Seventh, 
the relationship between bladder recurrence and survival in patients with UTUC 
after RNU remains controversial [43]. In this context, bladder recurrence was not 
defined as relapse-free failure in reference to a previous large-scale and 
worldwide retrospective study [44]; however, a different definition may yield a 
different result. Eighth, because of the limited diagnostic accuracy of preoperative 
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radiological examinations, all patients who could tolerate LND underwent the 
procedure according to our strategy. Therefore, several patients received LND 
despite the presence of low-stage cancer, and this may have affected the results. 
Finally, the blood sample used to calculate CONUT score was obtained 34.7 ± 
15.5 (mean ± standard deviation; median 32.0, range 6 – 62) days preoperatively. 
As the half-life of serum albumin is approximately 2-3 weeks, we should consider 
a possible time lag.  
 
Conclusions 
 This study indicated that preoperative CONUT score helped predict prognosis 
in patients with localized UTUC after RNU. This biomarker is objective and non-
invasive, and is easily obtained from blood samples in daily clinical practice. Thus, 
in addition to established prognostic factors, the CONUT score may improve 
postoperative follow-up performance, especially for patients with high CONUT 
scores.  
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Figure legends 
Figure 1: Flowchart showing patient selection 
RNU, radical nephroureterectomy; UTUC, urothelial carcinoma of the upper 
urinary tract; UC, urothelial carcinoma 
 
Figure 2: ROC curve analysis for CONUT score 
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We used the continuous variable CONUT as the test variable and RFS as the 
state variable. An investigation of the cut-off value for the CONUT score using the 
ROC curve showed the most appropriate cut-off value for the CONUT score to 
be 3 (AUC: 0.588). Thus, we set 3 as the cut-off value for the CONUT score in 
this study, and classified the patients into high (≥3) and low (<3) CONUT groups.  
ROC, receiver operating characteristics; CONUT, Controlling Nutritional Status; 
RFS, relapse-free survival; AUC, area under curve 
 
Figure 3: RFS, CSS, and OS according to CONUT score in patients with localized 
UTUC after RNU 
Survival curves according to CONUT score. The 5-year RFS, CSS, and OS were 
significantly lower in patients with high CONUT scores, compared to those with 
low CONUT scores (RFS: 50.1% vs. 66.0%, p = 0.0395; CSS: 28.1% vs. 71.7%, 
p = 0.0041; OS: 26.4% vs. 66.8%, p = 0.0140). 
RFS, relapse-free survival; CSS, cancer-specific survival; OS, overall survival; 
CONUT, Controlling Nutritional Status 
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Table 1: Definition of the CONUT score 
Parameter None Light Moderate Sever 
Serum albumin (g/dL) ≥ 3.50 3.00 – 3.49 2.50 – 2.99 < 2.50 
Score 0 2 4 6 
Total lymphocyte count (/mm3) ≥ 1600 1200 - 1599 800 - 1199 < 800 
Score 0 1 2 3 
Total cholesterol (mg/dL) ≥ 180 140 - 179 100 - 139 < 100 
Score 0 1 2 3 
CONUT, Controlling Nutritional Status 
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Table 2: Components of the CONUT score 
 Low CONUT 
(n = 83) 
High CONUT 
(n = 24) 
CONUT score 
 0 
 1 
 2 
 3 
 4 
 5 
 6     
 
21 (25.3%) 
40 (48.2%) 
22 (26.5%) 
0 
0 
0 
0 
 
0 
0 
0 
13 (54.2%) 
6 (25.0%) 
4 (16.7%) 
1 (4.17%) 
Albumin score 
 0 
 2 
 4 
 6 
 
82 (98.8%) 
1 (1.20%) 
0 
0 
 
15 (62.3%) 
8 (33.3%) 
1 (4.17%) 
0 
Total Lymphocyte score 
 0 
 1 
 2 
 3 
 
40 (48.2%) 
31 (37.8%) 
12 (14.5%) 
0 
 
2 (8.33%) 
3 (12.5%) 
12 (50.0%) 
7 (29.2%) 
Total cholesterol score 
 0 
 1 
 2 
 3 
 
60 (72.3%) 
19 (22.9%) 
4 (4.82%) 
0 
 
8 (33.3%) 
11 (45.8%) 
5 (20.8%) 
0 
CONUT, Controlling Nutritional Status 
 
 
29 
 
 
 
Table 3: Comparisons of patients’ backgrounds according to CONUT score 
Variable Low CONUT  
(n = 83) 
High CONUT 
(n = 24) 
p 
Age, years (continuous variable) a 72.7 ± 9.98 76.1 ± 8.65 0.166 
Age, years (categorical classification) 
 ≥ 70 (ref. < 70) 
 
48 (57.8%) 
 
19 (79.2%) 
0.0571 
Sex 
 Male (ref. female) 
 
51 (61.5%) 
 
17 (70.8%) 
0.400 
Initial symptom  
 Macrohematuria  
 No symptom with urinary cytology disorder  
 Hydronephrosis 
 Pain 
 Others  
 
52 (62.7%) 
6 (7.23%) 
8 (9.64%) 
6 (7.22%) 
11 (13.3%) 
 
17 (70.8%) 
0 
5 (20.8%) 
1 (4.17%) 
1 (4.17%) 
0.399 
Tumor site 
 Pelvis (ref. ureter) 
 
52 (62.7%) 
 
13 (54.2%) 
0.454 
Surgery type 
 Open (ref. laparoscopic) 
66 (78.6%) 20 (20.0%) 0.878 
pT stage 
  pTis 
pTa 
pT1 
pT2 
pT3 
pT4 
 
1 (1.20%) 
4 (4.82%) 
17 (20.5%) 
14 (16.9%) 
44 (53.0%) 
3 (3.61%) 
 
1 (4.17%) 
0 
6 (25.0%) 
3 (12.5%) 
12 (50.0%) 
2 (8.33%) 
0.882 
pN stage 
  pNx 
  pN0 
 
27 (32.5%) 
50 (60.2%) 
 
11 (45.8%) 
10 (41.7%) 
0.413 
30 
 
pN1 
  pN2 
3 (3.61%) 
3 (3.61%) 
0 
3 (12.5%) 
Tumor grade 
 High (ref. low) 
 
58 (69.9%) 
 
19 (79.2%) 
0.372 
LVI 
 With (ref. without) 
 
42 (50.6%) 
 
12 (50.0%) 
0.959 
Adjuvant chemotherapy  
 With (ref. without) 
8 (9.52%) 0 (0.00%) 0.109 
CRP, mg/dl 
 ≥0.5 (ref. <0.5) 
 
10 (12.1%) 
 
9 (37.5%) 
0.0041 
Sarcopenia  
 With (ref. without) 
52 (62.7%) 21 (87.5%) 0.0213 
Relapse of cancer 
 With (ref. without) 
24 (28.9%) 10 (41.7%) 0.237 
Death from cancer 
 With (ref. without) 
16 (19.3%) 9 (37.5%) 0.0632 
Death from any cause 
 With (ref. without)  
22 (26.5%) 10 (41.7%) 0.153 
Follow-up, months a  46.1 ± 32.8 25.5 ± 18.4 0.0045 
a 
Mean ± standard deviation  
CONUT, Controlling Nutritional Status; LVI, lymphovascular invasion; CRP, C-
reactive protein 
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Table 4: Multivariable analysis for the predictive factors for RFS, CSS, and OS in patients with localized UTUC after RNU 
Variable RFS 
(95% CI) 
p CSS 
(95% CI) 
p OS 
(95% CI) 
p 
pT stage 
 ≥3 (ref. <3) 
2.02 (0.83 – 5.51) 0.122 12.9 (3.01 – 91.3) 0.0002 3.29 (1.23 – 10.1) 0.0167 
pN stage  
 ≥1 (ref. 0 or X) 
3.59 (1.43 – 8.28) 0.0080 3.11 (0.97 – 8.57) 0.0548 1.98 (0.64 – 5.11) 0.215 
Tumor grade 
 High (ref. low) 
4.21 (0.99 – 28.9) 0.0525 1.88 (0.45 – 9.49) 0.390 2.64 (0.79 – 10.4) 0.117 
LVI 
 With (ref. without) 
1.47 (0.61 – 4.02) 0.403 1.49 (0.48 – 4.04) 0.470 1.31 (0.50 – 3.15) 0.564 
CRP, mg/dl 
 ≥0.5 (ref.< 0.5) 
1.12 (0.49 – 2.68) 0.796 1.08 (0.42 – 2.64) 0.867 1.20 (0.51 – 2.71) 0.669 
CONUT 
 ≥3 (ref. <3) 
2.26 (0.97 – 4.94) 0.0581 5.44 (1.95 – 14.8) 0.0016 2.90 (1.18 – 6.75) 0.0214 
RFS, relapse-free survival; CSS, cancer-specific survival; OS, overall survival; UTUC, urothelial carcinoma of the upper 
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urinary tract; RNU, radical nephroureterectomy; HR, hazard ratio; CI, confidence interval; LVI, lymphovascular invasion; 
CRP, C-reactive protein CONUT, Controlling Nutritional Status



